BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26813159)

  • 1. Urinary adverse effects of pelvic radiotherapy.
    Liberman D; Mehus B; Elliott SP
    Transl Androl Urol; 2014 Jun; 3(2):186-95. PubMed ID: 26813159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term urinary adverse effects of pelvic radiotherapy.
    Elliott SP; Malaeb BS
    World J Urol; 2011 Feb; 29(1):35-41. PubMed ID: 20959990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
    Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validating a claims-based method for assessing severe rectal and urinary adverse effects of radiotherapy.
    Sewell JM; Rao A; Elliott SP
    Urology; 2013 Aug; 82(2):335-40. PubMed ID: 23746713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer.
    Mayer EN; Tward JD; Bassett M; Lenherr SM; Hotaling JM; Brant WO; Lowrance WT; Myers JB
    BJU Int; 2017 May; 119(5):700-708. PubMed ID: 27469289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
    Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy.
    Cheng JC; Peng LC; Chen YH; Huang DY; Wu JK; Jian JJ
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1010-8. PubMed ID: 14575832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
    Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propensity-Weighted Comparison of Long-Term Risk of Urinary Adverse Events in Elderly Women Treated For Cervical Cancer.
    Elliott SP; Fan Y; Jarosek S; Chu H; Downs L; Dusenbery K; Geller MA; Virnig BA
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):586-93. PubMed ID: 25890845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer.
    Jereczek-Fossa BA; Jassem J; Badzio A
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):476-82. PubMed ID: 11872295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
    Kupelian PA; Reddy CA; Klein EA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image-guided intensity-modulated radiotherapy for prostate cancer: Dose constraints for the anterior rectal wall to minimize rectal toxicity.
    Peterson JL; Buskirk SJ; Heckman MG; Diehl NN; Bernard JR; Tzou KS; Casale HE; Bellefontaine LP; Serago C; Kim S; Vallow LA; Daugherty LC; Ko SJ
    Med Dosim; 2014; 39(1):12-7. PubMed ID: 24099966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
    Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
    Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.